Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest VIVUS Inc. Stories

2011-10-14 05:45:00

MOUNTAIN VIEW, Calif., Oct. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 2011 BioCentury NewsMakers in the Biotech Industry Conference. The VIVUS presentation will take place at the Millennium Broadway Hotel in New York, NY on Friday, October 21, 2011 at 10:00 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com. About...

2011-10-03 07:45:00

MOUNTAIN VIEW, Calif., Oct. 3, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented at Obesity 2011: The 29(th) Annual Scientific Meeting of The Obesity Society being held in Orlando, Florida. The presentations highlighted the long-term beneficial effects of Qnexa(®) treatment in addition to double-digit weight loss. Specifically, Qnexa patients had significant...

2011-09-29 05:45:00

MOUNTAIN VIEW, Calif., Sept. 29, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at Obesity 2011, the 29th Annual Scientific Meeting of The Obesity Society, to be held October 1st to October 5th, 2011 in Orlando, Florida. The Obesity Society's Annual Scientific Meeting has grown to be one of the largest gatherings of obesity professionals worldwide. The posters will be displayed in the Cypress Ballroom of the Orlando World Center...

2011-09-26 05:45:00

MOUNTAIN VIEW, Calif., Sept. 26, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that a poster authored by Dr. Mark W. Green, Director of the Center for Headache and Pain Medicine and Professor of Neurology and Anesthesiology at the Mount Sinai School of Medicine, will be presented at the American Neurological Association (ANA) Meeting in San Diego, CA. In addition to the topiramate exposure data previously reported, the results will include the rate of major congenital...

2011-09-22 05:45:00

MOUNTAIN VIEW, Calif., Sept. 22, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) reported that in the opening keynote address at the 6th Annual Obesity and Wellness Congress in Washington DC today, Kenneth E. Thorpe, PhD stated that 10% weight loss in patients age 60 to 64 may be able to provide Medicare savings of $8 billion over ten years and $35 billion over their lifetime. The meeting included Chief Medical Officers of Health Plans, Payers, Health Systems and Hospitals as well as...

2011-09-16 05:45:00

MOUNTAIN VIEW, Calif., Sept. 16, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting in Lisbon, Portugal. The presentations highlighted the long-term beneficial effects of QNEXA treatment in metabolically-impaired patients with prediabetes, diabetes, and metabolic syndrome. The QNEXA presentations included: Decreased Progression to Diabetes in Subjects...

2011-09-15 05:45:00

MOUNTAIN VIEW, Calif., Sept. 15, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that following a recent teleconference it has reached agreement with officials of the Endocrine and Metabolic Division of the Food and Drug Administration on a plan that allows for an early resubmission of the QNEXA New Drug Application for the treatment of obesity. The resubmission plan allows VIVUS to seek approval for an initial indication that includes obese men and women of non-child...

2011-09-13 05:45:00

MOUNTAIN VIEW, Calif., Sept. 13, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today presented positive results from the avanafil phase 3 study in diabetics. In the REVIVE-Diabetes study (TA-302), male diabetics receiving avanafil had significant improvement in erectile function. Dr. Irwin Goldstein, Director of Sexual Medicine at Alvarado Hospital, San Diego, CA, presented the results of the study during the poster session at the 47th European Association for the Study of Diabetes...

2011-09-01 15:00:00

MOUNTAIN VIEW, Calif., Sept. 1, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's new drug application (NDA) for its investigational drug candidate, avanafil, for the treatment of erectile dysfunction (ED). The target date for the FDA to complete its review of the avanafil NDA is April 29, 2012. In previously announced results from the pivotal phase 3 trials, patients treated with avanafil...

2011-08-31 05:45:00

MOUNTAIN VIEW, Calif., Aug. 31, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that VIVUS management, including Leland Wilson, Chief Executive Officer; Timothy Morris, Chief Financial Officer, and Wesley W. Day, Ph.D., Vice President, Clinical Development, will participate in three investment conferences during the month of September. The conference presentation schedule is as follows: Stifel Nicolaus 2011 Healthcare ConferenceWednesday, September 7, 20118:00 a.m....